- Home
- AAMI vs AZTA Comparison
AAMI vs AZTA Comparison
Compare AAMI & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAMI
- AZTA
- Stock Information
- Founded
- AAMI 1980
- AZTA 1978
- Country
- AAMI United States
- AZTA United States
- Employees
- AAMI N/A
- AZTA N/A
- Industry
- AAMI Investment Managers
- AZTA Industrial Machinery/Components
- Sector
- AAMI Finance
- AZTA Technology
- Exchange
- AAMI Nasdaq
- AZTA Nasdaq
- Market Cap
- AAMI 1.6B
- AZTA 1.4B
- IPO Year
- AAMI N/A
- AZTA 1995
- Fundamental
- Price
- AAMI $46.78
- AZTA $29.65
- Analyst Decision
- AAMI Hold
- AZTA Strong Buy
- Analyst Count
- AAMI 4
- AZTA 5
- Target Price
- AAMI $43.50
- AZTA $41.20
- AVG Volume (30 Days)
- AAMI 243.7K
- AZTA 451.3K
- Earning Date
- AAMI 10-30-2025
- AZTA 11-10-2025
- Dividend Yield
- AAMI 0.08%
- AZTA N/A
- EPS Growth
- AAMI 43.58
- AZTA N/A
- EPS
- AAMI 2.41
- AZTA N/A
- Revenue
- AAMI $538,200,000.00
- AZTA $668,821,000.00
- Revenue This Year
- AAMI $21.42
- AZTA N/A
- Revenue Next Year
- AAMI $19.07
- AZTA $4.10
- P/E Ratio
- AAMI $19.99
- AZTA N/A
- Revenue Growth
- AAMI 18.76
- AZTA 12.46
- 52 Week Low
- AAMI $22.60
- AZTA $23.91
- 52 Week High
- AAMI $54.99
- AZTA $55.64
- Technical
- Relative Strength Index (RSI)
- AAMI 46.05
- AZTA 42.96
- Support Level
- AAMI $48.55
- AZTA $29.67
- Resistance Level
- AAMI $54.99
- AZTA $31.70
- Average True Range (ATR)
- AAMI 1.78
- AZTA 1.25
- MACD
- AAMI 0.06
- AZTA -0.25
- Stochastic Oscillator
- AAMI 19.58
- AZTA 17.08
About AAMI Acadian Asset Management Inc. Common Stock
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.